GlassScriptPhysician profile
Robert H Perkins
NPI 1912057449
$12,654.54
in general payments reported to CMS, 2019-2025
27 companies · $1,034 in 2025
The $1,034 reported for 2025 was more than what 88% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
See the full distribution for Physical Medicine & Rehabilitation
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,270 · 2020: $1,575 · 2021: $1,177 · 2022: $1,293 · 2023: $3,614 · 2024: $1,692 · 2025: $1,034.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,933 · Travel and Lodging: $1,407.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,933.10 |
| Travel and Lodging | $1,407.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $3,617.72 | 2021-2025 | Intellis Adaptivestim, Accurian, Synchromedii |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,414.44 | 2019-2025 | Relistor |
| Collegium Pharmaceutical, INC. | $1,368.38 | 2019-2025 | Xtampza, Belbuca |
| Abbvie INC. | $1,230.28 | 2021-2025 | |
| Boston Scientific Corporation | $853.73 | 2019-2025 | Wavewriter Alpha Prime 16, General - Therapies, General - Pain Management |
| Pfizer INC. | $748.88 | 2019-2023 | |
| Medtronic USA, INC. | $603.48 | 2019-2020 | |
| Abbott Laboratories | $601.46 | 2019-2025 | Eterna |
| Nevro Corp. | $477.50 | 2019-2021 | |
| Vertex Pharmaceuticals Incorporated | $274.43 | 2025 | |
| Mdd US Operations, LLC | $247.02 | 2019-2020 | |
| Scilex Pharmaceuticals INC. | $240.56 | 2019-2020 | |
| Allergan, INC. | $183.72 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $147.79 | 2022 | |
| Biodelivery Sciences International, INC. | $130.13 | 2019-2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $113.33 | 2019-2021 | |
| Amgen INC. | $77.81 | 2019-2022 | |
| Biotronik Nro, INC. | $56.92 | 2025 | Prospera |
| Vertical Pharmaceuticals, LLC | $50.23 | 2019 | |
| Impel Pharmaceuticals INC. | $49.44 | 2023 | Trudhesa |
| Zyla Life Sciences, INC. | $38.63 | 2019-2020 | |
| Merz Pharmaceuticals, LLC | $33.22 | 2025 | Xeomin |
| Kaleo, INC. | $28.29 | 2019 | |
| Tonix Medicines, INC. | $20.73 | 2025 | Tonmya |
| Ibsa Pharma INC. | $20.36 | 2021 | |
| Shionogi INC | $13.95 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $12.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Perkins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.